Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV16 E6/E7 SLP vaccine with or without imiquimod in HPV16-positive vulvar intraepithelial neoplasia
2007-005230-37Phase 2Suspended
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2008
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in vulvar intraepithelial neoplasia (VIN) comparing HPV16 E6/E7 SLP vaccine + imiquimod with HPV16 E6/E7 SLP vaccine alone (2 arms). Primary endpoint: Systemic immunological response. Started Feb 2008; status: suspended.
02
Drugs
hpv16 e6/e7 synthetic long peptide vaccineimiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2007-005230-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005230-37.